Novel GLP-1/GIP receptor agonist effective for chronic weight management

Also, the patients receiving VK2735 15 mg achieved a remarkable mean placebo-adjusted body weight reduction of 13.1% by week 13, with an impressive 88% of individuals experiencing a placebo-adjusted weight reduction of 10% or more. These results underscore the potential of VK2735 as a game-changer in combating obesity.

The CEO of Viking Therapeutics, expressed enthusiasm over the outcomes of the trial highlighting the promising efficacy and tolerability profile of VK2735. Despite a 20% discontinuation rate among VK2735 recipients, safety analysis revealed mostly mild to moderate drug-related adverse events, with nausea being the most prevalent.

Viking Therapeutics outlined plans for further development of VK2735, including discussions with the FDA and the release of Phase 1 data for an oral formulation of the drug in the upcoming weeks. The CEO affirmed the commitment of the company to advance this vital therapy by signaling optimism for its progression into later clinical stages.

The positive results from the VENTURE trial mark a significant step in the pursuit of effective treatments for obesity and related comorbidities. VK2735 demonstrates promising efficacy and manageable safety profile to address the unmet needs in chronic weight management for patients seeking alternative therapeutic options.

Reference:

Viking therapeutics announces positive top-line results from phase 2 VENTURE trial of dual GLP-1/GIP receptor agonist VK2735 in patients with obesity. (n.d.). Viking Therapeutics InvestorRoom. Retrieved March 1, 2024, from https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity